

China International Capital Corporation Hong Kong Securities Limited
29/F, One International Finance Centre,
1 Harbour View Street Central
Hong Kong

Date: March 12, 2024

Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司
Room 1310, Building 1
No. 907 Yaocheng Avenue
Taizhou, Jiangsu
PRC

Attention: The Board of Directors

Dear Sirs,

Consent to the issue of the Prospectus of Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 (the “Company”)

We, China International Capital Corporation Hong Kong Securities Limited, as the sole sponsor, refer to the prospectus of the Company dated March 12, 2024 (the “**Prospectus**”) in connection with the global offering and proposed listing of the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We hereby give, and confirm we have not withdrawn, our consent to the issue of the Prospectus and the inclusion therein of, and all references thereto, our name, qualification, confirmations and opinions, in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing this letter to the Registrar of Companies in Hong Kong and the Stock Exchange for the purpose of registration of the Prospectus and referring to it in the Prospectus. We also hereby consent to a copy of this letter being made available on display as described in the Prospectus.

For and on behalf of
China International Capital Corporation Hong Kong Securities Limited

A handwritten signature in black ink, appearing to be 'Ka Siu Chu', written over a horizontal line.

Name: Ka Siu Chu
Title: Vice President



KPMG
8th Floor, Prince's Building
Central, Hong Kong
G P O Box, Hong Kong
Telephone +852 2522 6022
Fax +852 2845 2588
Internet kpmg.com/cn

毕马威会计师事务所
香港中环遮打道10号
太子大厦8楼
香港邮政总局信箱50号
电话 +852 2522 6022
传真 +852 2845 2588
网址 kpmg.com/cn

The Board of Directors
Qyuns Therapeutics Co., Ltd.
Room 1310, Building 1, No.907 Yaocheng Avenue,
Taizhou, Jiangsu Province
PRC

Your ref: FL/CP7

12 March 2024

Dear Sirs

We refer to the prospectus dated 12 March 2024 in connection with the proposed initial listing of shares of Qyuns Therapeutics Co., Ltd. (the "Company") on the Main Board of The Stock Exchange of Hong Kong Limited (the "Prospectus"), a copy of which is attached and stamped by us on its front cover for the purpose of identification.

We hereby consent to the inclusion of our accountants' report dated 12 March 2024 on the historical financial information for the years ended 31 December 2021 and 2022 and the nine months ended 30 September 2023 and our report dated 12 March 2024 on the pro forma financial information as at 30 September 2023 in the Prospectus, and the references to our name in the form and context in which they are included.

Yours faithfully

Certified Public Accountants
Hong Kong

IMPORTANT

IMPORTANT: If you are in any doubt about any of the contents of this prospectus, you should seek independent professional advice.



Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

| | |
|--|--|
| Number of Offer Shares under the Global Offering | : 12,046,400 H Shares |
| Number of Hong Kong Offer Shares | : 1,204,800 H Shares (subject to reallocation) |
| Number of International Offer Shares | : 10,841,600 H Shares (subject to reallocation) |
| Maximum Offer Price | : HK\$20.20 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund) |
| Nominal Value | : RMB1.00 per H Share |
| Stock Code | : 2509 |

Sole Sponsor, Sponsor-Overall Coordinator



Joint Global Coordinators, Overall Coordinators,
Joint Bookrunners and Joint Lead Managers




Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



Joint Bookrunners and Joint Lead Managers



Joint Lead Managers



Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.

A copy of this prospectus, having attached thereto the documents specified in "Appendix IX—Documents Delivered to the Registrar of Companies and Documents on Display—A. Documents Delivered to the Registrar of Companies" to this prospectus, has been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission and the Registrar of Companies in Hong Kong take no responsibility for the contents of this prospectus or any other document referred to above.

The Offer Price is expected to be fixed by agreement between the Overall Coordinators (for themselves and on behalf of the Underwriters) and us on the Price Determination Date. The Price Determination Date is expected to be on or around Monday, March 18, 2024 (Hong Kong time) and, in any event, not later than 12:00 noon on Monday, March 18, 2024 (Hong Kong time). The Offer Price will be not more than HK\$20.20 per Offer Share and is currently expected to be not less than HK\$19.80 per Offer Share. If, for any reason, the Offer Price is not agreed by 12:00 noon on Monday, March 18, 2024 (Hong Kong time) between the Overall Coordinators (for themselves and on behalf of the Underwriters) and us, the Global Offering will not proceed and will lapse.

Applicants for Hong Kong Offer Shares may be required to pay, on application (subject to application channels), the maximum Offer Price of HK\$20.20 for each Hong Kong Offer Share together with brokerage fee of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, subject to refund if the Offer Price as finally determined is less than HK\$20.20 per Hong Kong Offer Share.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for, and to procure applicants for the subscription for, the Hong Kong Offer Shares are subject to termination by the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) if certain grounds arise prior to 8:00 a.m. on the day that trading in the H Shares commences on the Stock Exchange. Such grounds are set out in "Underwriting—Underwriting Arrangements and Expenses—The Hong Kong Public Offering—Grounds for Termination" in this prospectus.

The Offer Shares have not been, and will not be, registered under the U.S. Securities Act or any state securities laws in the United States and may not be offered, sold, pledged or otherwise transferred within the United States or to U.S. Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. The Offer Shares may be offered and sold only outside the United States to persons that are not, and are not acting for the account or benefit of, U.S. Persons in offshore transactions in reliance on Regulation S. There has been and will be no public offering of the H Shares in the United States.

ATTENTION

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this prospectus to the public in relation to the Hong Kong Public Offering.

This prospectus is available at the website of the Stock Exchange at www.hkexnews.hk and our website at www.qyuns.net. If you require a printed copy of this prospectus, you may download and print from the website addresses above.

March 12, 2024



12 March 2024

The Board of Directors

Qyuns Therapeutics Co., Ltd. (江苏荃信生物醫藥股份有限公司)(the “Company”)

Room 1310, Building 1

No. 907 Yaocheng Avenue

Taizhou, Jiangsu

PRC

Dear Sirs/Madams,

We refer to the prospectus of the Company dated 12 March 2024 (the “**Prospectus**”) in connection with the Company’s proposed global offering and listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

We hereby give, and confirm that we have not withdrawn, our written consent to the issue of the Prospectus by the Company, with the inclusion therein of all references to our name, qualification, confirmations, opinions and reports in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing a copy of this letter to the Registrar of Companies in Hong Kong and the Stock Exchange and referring to it in the Prospectus.

We also consent to making a copy of this letter and our legal opinion available on display as described in the Prospectus.

-signature page to follow-

For and on behalf of
JunHe LLP

JunHe LLP.

12 March 2024

The Board of Directors

Qyuns Therapeutics Co., Ltd. (江苏荃信生物醫藥股份有限公司)(the "Company")

Room 1310, Building 1

No. 907 Yaocheng Avenue

Taizhou, Jiangsu

PRC

Dear Sirs/Madams,

We refer to the prospectus of the Company dated 12 March 2024 (the "**Prospectus**") in connection with the Company's proposed global offering and listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

We hereby give, and confirm that we have not withdrawn, our written consent to the issue of the Prospectus by the Company, with the inclusion therein of all references to our name, qualification, confirmations, opinions and reports in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing a copy of this letter to the Registrar of Companies in Hong Kong and the Stock Exchange and referring to it in the Prospectus.

We also consent to making a copy of this letter and our industry report available on display as described in the Prospectus.

-signature page to follow-

F R O S T & S U L L I V A N

沙 利 文

上海市静安区南京西路1717号
会德丰国际广场2504室
2504 Wheelock Square
1717 Nanjing West Road
Shanghai 200040, China
Tel: 86 (21) 5407 5836
Fax: 86 (21) 3209 8500
www.frost.com

Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.



Name: Charles Lau
Title: Executive Director



CONSULTING & APPRAISAL

亞太評估

12 March 2024

The Board of Directors

Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司)(the "Company")

Room 1310, Building 1

No. 907 Yaocheng Avenue

Taizhou, Jiangsu

PRC

Dear Sirs/Madams,

We refer to the prospectus of the Company dated 12 March 2024 (the "**Prospectus**") in connection with the Company's proposed global offering and listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

We hereby give, and confirm that we have not withdrawn, our written consent to the issue of the Prospectus by the Company, with the inclusion therein of all references to our name, qualification, confirmations, opinions and reports in the form and context in which they respectively appear in the Prospectus.

We hereby consent to you releasing a copy of this letter to the Registrar of Companies in Hong Kong and the Stock Exchange and referring to it in the Prospectus.

We also consent to making a copy of this letter and our industry report available on display as described in the Prospectus.

-signature page to follow-

Asia-Pacific Consulting and Appraisal Limited



David G.D. Cheng

MRICS

Executive Director